For a more comprehensive look at how oral GLP-1 receptor agonists fit into a holistic approach to diabetes management, check out: Understanding GLP-1 Receptor Agonists
The magnitude of weight regain observed across multiple high-quality randomized controlled trials underscores the chronic and relapsing nature of obesity, reflecting underlying physiological compensatory mechanisms, such as hormonal dysregulation and reduced energy expenditure
Surprisingly, GLP-1RAs, such as liraglutide, lixisenatide, and semaglutide, have showed outstandingly neuroprotective effects on animal models of PD (63, 64)
Several large studies using electronic health records and insurance claims data have tracked people using GLP-1 medications for five years or more
You are walking through a security checkpoint carrying needles, syringes, and liquid vials